Showing results (1141-1150 of 1,344) with videos related to

Sort By:
Pageof 135
The Pharmacogenomics Journal|September 14, 2011
A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patientsM Tohkin, N Kaniwa, Y Saito, et al.
The Pharmacogenomics Journal|August 25, 2011
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort studyG Yimer, W Amogne, A Habtewold, et al.
The Pharmacogenomics Journal|August 10, 2011
DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesiaS Tanaka, A Syu, H Ishiguro, et al.
The Pharmacogenomics Journal|August 10, 2011
Background gene expression networks significantly enhance drug response prediction by transcriptional profilingA Torkamani, N J Schork
The Pharmacogenomics Journal|October 12, 2011
ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki diseaseY Onouchi, Y Suzuki, H Suzuki, et al.
The Pharmacogenomics Journal|February 29, 2012
Pharmacogenetics of asthma controller treatmentE B Mougey, C Chen, K G Tantisira, et al.
The Pharmacogenomics Journal|August 14, 2018
An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>CNyarai Desiree Soko, Emile Chimusa, Collen Masimirembwa, et al.
The Pharmacogenomics Journal|September 22, 2018
Genetic markers in methotrexate treatmentsAndrea Giletti, Patricia Esperon
The Pharmacogenomics Journal|September 22, 2018
HLA-C*12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactionsSijia Yan, Hao Xiong, Fengmin Shao, et al.
The Pharmacogenomics Journal|September 26, 2018
Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adultsSze Ling Chan, Hong Yen Ng, Cynthia Sung, et al.
Pageof 135